leucine Report issue

Small molecule Experimental
AACT ChEMBL DrugBank Drug Central KEGG MeSH PubChem

Active Ingredient History

NOW
  • Now
Leucine is an α-amino acid used in the biosynthesis of proteins. Leucine is an essential hydrophobic amino acid. It is used in the Leucine may be used some people as a supplement to build muscle. Leucine is also found in fish, meat, and poultry. In the pharmaceutical industry, L-leucine is used for parenteral and enteral nutrition and feeding, and is also used as a flavoring product and tablet lubricant in manufacturing. Leucine is an mTOR activator. It is a dietary amino acid with the capacity to directly stimulate muscle protein synthesis. As a dietary supplement, leucine has been found to slow the degradation of muscle tissue by increasing the synthesis of muscle proteins in aged rats. Long-term leucine supplementation does not increase muscle mass or strength in healthy elderly men. Leucine potently activates the mammalian target of rapamycin kinase that regulates cell growth. Infusion of leucine into the rat brain has been shown to decrease food intake and body weight via activation of the mTOR pathway.   NCATS

Chemistry

  • SMILES: CC(C)C[C@H](N)C(O)=O
  • InChIKey: ROHFNLRQFUQHCH-YFKPBYRVSA-N
  • Mol. Mass: 131.1729
  • ALogP: 0.44
  • ChEMBL Molecule:
    leucine  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Missing data
  • Delivery Methods: Missing data
  • Pro Drug: No

Alternative names

2-amino-4-methylvaleric acid | (2s)-2-amino-4-methylpentanoic acid | (2s)-alpha-2-amino-4-methylvaleric acid | (2s)-alpha-leucine | chick pea extractvitamin c, l-leucine, vegetable capsule (hypromellose) | e641 | l | leu | leucine | l-leucin | l-leucine | l-leuzin | (s)-leucine | (s)-(+)-leucine

Organizations (67)

Research & Development (67)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (20)

Approved Indications (1)


 

Burns (approved 1971)

Experimental Indications - Clinical Trial Phases 1-4 (19)


 

Aging (Phase 1/Phase 2)

Anemia, Diamond-Blackfan (Phase 2)

Anemia, Hypoplastic, Congenital (Phase 1/Phase 2)

Atrophy (Phase 1/Phase 2)

Constipation (Phase 2)

Depression (Early Phase 1)

Depressive Disorder, Major (Phase 2)

Dietary Supplements ()

Frail Elderly (Phase 1)

Healthy Volunteers (Phase 1)

Hyperoxaluria (Phase 1/Phase 2)

Liver Cirrhosis (Phase 4)

Metabolic Syndrome (Phase 2)

Muscle Hypotonia (Phase 3)

Non-alcoholic Fatty Liver Disease (Phase 2)

Obesity (Phase 2)

Red-Cell Aplasia, Pure (Phase 2)

Sarcopenia (Phase 2/Phase 3)

Vitamin B 6 Deficiency (Phase 2/Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 65
  • # of Trial Organizations: 67

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue